Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02260661
Other study ID # D6140C00001
Secondary ID
Status Completed
Phase Phase 1
First received October 6, 2014
Last updated October 7, 2016
Start date November 2014
Est. completion date July 2016

Study information

Verified date October 2016
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

First time in patients study of AZD8835. The study has four parts. Part A AZD8835 is administered as a single agent in a multiple ascending dose escalation phase to investigate dose level for monotherapy. Part B follows the multiple ascending dose phase, additional patients with tumors with documented PIK3CA gene mutation will be enrolled to a single dose expansion phase. Part C is a second dose escalation phase in which post-menopausal patients with estrogen receptor positive (ER+), HER2 negative breast cancer will receive AZD8835 in combination with fulvestrant. Part D follows the combination dose escalation phase of the study, additional postmenopausal patients with ER+/HER2 negative breast cancer with documented PIK3CA gene mutation will be enrolled to a AZD8835 and fulvestrant combination dose-expansion phase at maximum tolerated dose or recommended phase II dose.


Description:

AZD8835 is a novel small molecule that inhibits cancer progression by blocking PI3 kinase pathway components p110α and p110δ.

In this first-time-in-patient study, AZD8835 will initially be administered as a single agent to patients with advanced solid malignancies. Patients will be treated at a starting dose of 20 mg twice daily (BID), administered weekly on Days 1 and 4 and will be escalated to reach a maximum-tolerated dose (MTD) in patients as defined by dose-limiting toxicities (DLTs). A BID intermittent dosing schedule administered weekly on Days 1 and 4 of an oral formulation of AZD8835 will be used, as deemed optimal and effective in non-clinical studies, primarily to determine the safety and tolerability of AZD8835. The pharmacokinetics (PK) of AZD8835 and potential biological activity will also be investigated. In Part A of this study, AZD8835 will be administered as a single agent in a multiple ascending dose escalation phase to investigate the appropriate monotherapy dose level for clinical use. Additional dosing schedules may be studies, including dosing on Days 1 and 2 of each week, rather than Days 1 and 4.

Backfilled pharmacodynamic (PDc) cohorts in selected patients with tumours that have documented mutations in the phosphatidylinositol-4,5- bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene will allow further preliminary assessment of the biological effect of AZD8835 in these patients.

Following the single-agent dose-escalation phase of the study, additional patients with tumours that have documented mutations in the PIK3CA gene will be enrolled to a single-agent dose-expansion phase at the MTD or recommended Phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, PK, and biological activity at the selected dose (Part B).

In addition, a further dose-escalation phase will be initiated following the observation of specific pre-determined criteria in the single-agent dose escalation, in which postmenopausal patients with oestrogen receptor positive (ER+), HER2 negative breast cancer will receive AZD8835 in combination with fulvestrant (Part C). The combination dose-escalation phase will investigate the appropriate combination dose level for clinical use.

Following the combination dose-escalation phase of the study, additional postmenopausal patients with ER+ breast cancer and tumours with documented mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose-expansion phase at the MTD or RP2D (as appropriate) to explore further the safety, tolerability, PK, and biological activity at the selected dose (Part D).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria:

1. Part A: Histological or cytological confirmation of a solid tumor and disease progression. Part B: Histological or cytological confirmation of ER positive, HER2 negative breast cancer and disease progression or any other solid tumor with a PIK3CA gene mutation. Part C: Histological or cytological confirmation of ER positive, HER2 negative postmenopausal breast cancer with locally advanced or metastatic disease that is eligible for fulvestrant treatment. Part D: Histological or cytological confirmation of ER positive, HER2 negative postmenopausal breast cancer with locally advanced or metastatic disease that is eligible for fulvestrant treatment. Patients must also present with a tumor related mutation of the PIK3CA gene.

2. Availability of archival tumour tissue sample. If archival sample is not available, a fresh tumour biopsy must be provided.

3. At least one measurable lesion per RECIST v1.1. However, breast cancer patients with only bone disease are also eligible.

4. ECOG Performance Status 0-1.

5. Adequate organ function at baseline:

1. Serum total bilirubin = 1.5 x ULN and AST/SGOT and ALT/SGPT = 2.5 x ULN or = 5 x ULN if liver metastases are present.

2. Creatinine = 1.5 x ULN, or calculated or measured creatinine clearance = 50 mL/min, or 24-hour measured urine creatinine clearance = 50 mL/min.

3. Platelets = 100 x 10^9, Hb = 90 g/L, ANC = 1.5 x 10^9/L.

4. aPTT = 1.5 x ULN

5. Fasting glucose < 140 mg/dL (7.8 mmol/L).

6. Glycated haemoglobin (HbA1c) < 8%

6. Female patients and male patients with female partners of child bearing potential must be using adequate contraception.

Exclusion Criteria:

1. Recent chemotherapy, radiotherapy, hormonal therapy, immunotherapy or investigational drugs within 21 days or 5 half-days from enrolment.

2. Received palliative/focal radiotherapy within 2 weeks of first dose of study treatment.

3. Major surgery = 21 days from beginning of study drug

4. Any of the following cardiac criteria: CHF > Class II, cardiac ventricular arrhythmia requiring therapy, unstable angina or new-onset angina, QTcF interval >470ms, abnormal ECHO or MUGA at baseline (LVEF <50%).

5. Leptomeningeal disease

6. Part A: Intolerable AEs due to other PI3K inhibitors, dual PI3K and mTOR inhibitors or AKT inhibitors. Parts B, C, and D: Prior exposure to any of the following: pharmacological inhibitors of AKT, PI3K, or dual PI3K and mTOR kinase activity

7. Strong inhibitors and potent inducers of CYP3A4

8. Peripheral neuropathy CTCAE v4.03 Grade = 3

9. Diarrhoea CTCAE v4.03 Grade = 2

10. Acute or chronic pancreatitis

11. Clinically manifest diabetes mellitus, history of gestational diabetes mellitus and/or known glucose intolerance.

12. Patients currently receiving any medication that has the potential to prolong the QT interval or induce Torsades de Pointes

13. Spinal cord compression or brain metastases unless asymptomatic and not requiring steroids for at least 4 weeks

14. Patients in the combination arms - known hypersensitivity to fulvestrant

15. Therapeutic treatment with Coumadin or any other coumarin-derivative anticoagulant

16. Impaired GI function or GI disease that may interfere with absorption of AZD8835 or patients unable to take oral medication

17. As judged by the investigator any evidence of severe or uncontrolled systemic disease

18. Patients treated with hematopoietic colony-stimulating growth factors e.g., G-CSF, GM-CSF, M-CSF) = 2 weeks prior to start. Erythropoietin or darbepoetin is allowed if it was initiated at least 2 weeks prior to entry

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
AZD8835
AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
AZD8835
AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
AZD8835 in combination with fulvestrant
AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
AZD8835 in combination with fulvestrant
AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy

Locations

Country Name City State
United Kingdom Research Site Cambridge
United Kingdom Research Site London
United Kingdom Sarah Cannon Research Institute, United Kingdom London
United Kingdom Research Site Manchester
United States Research Site Denver Colorado
United States Research Site Greenville South Carolina
United States Research Site Houston Texas
United States Research Site Milwaukee Wisconsin
United States Research Site Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the maximum tolerated dose (MTD) or recommended Phase II dose of oral AZD8835 as a single agent and in combination with fulvestrant MTD - A dose will be considered non-tolerated and dose escalation will stop if 2 or more of up to 6 evaluable patients experience a dose limiting toxicity at a dose level. Once the non-tolerated dose is defined, the MTD will be confirmed at the previous dose level below the non-tolerated dose or a dose between the non-tolerated dose and the last tolerated dose my be investigated. A minimum of 6 evaluable patients are required to determine the MTD. Recommended Phase II dose - A minimum of 6 evaluable patients is necessary to determine the recommended dose. A dose will be considered non-tolerated and dose escalation will stop if 2 or more patients experience a dose dose limiting toxicity at a dose level. At the end of one cycle of treatment No
Primary Establish the preliminary safety and tolerability profile of oral AZD8835 as a single agent and in combination with fulvestrant Assessed in terms of adverse events and laboratory data that is collected on all patients Up to a projected 36 months Yes
Secondary To establish the pharmacokinetic profile of oral AZD8835 as a single agent and in combination with fulvestrant Venous blood samples (2 mL) for determination of concentrations of AZD8835 and the investigation of AZ8835 metabolites in plasma will be taken during Parts A, B, C, D Venous blood samples will be collected pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 96 hours post dose - exact schedule varies according to Part A, B, C, or D No
Secondary To evaluate the preliminary efficacy and anti-tumor activity of oral AZD8835 as a single agent or in combination with fulvestrant Categorization of objective tumor response will be based on RECIST v1.1 guidelines for complete response, partial response, stable disease, or progression of disease Tumour response will be assessed at the completion of Cycle 2 (Week 8) and patients will be restaged after every 8 weeks for up to 1 year and every 12 weeks thereafter; assessments should be performed until disease progression. No
Secondary To evaluate the pharmacodynamic (PDc) effect of oral AZD8835 as a single agent and in combination with fulvestrant Tumor samples will be analyzed to assess PRAS40 phosphorylation, AKT phosphorylation, S6 phosphorylation, FOXO3a localisation Tumour biopsies will be collected: (1) at pretreatment, (2) at one on-treatment time point (preferably Cycle 2 Day 1), and (3) at end of study treatment (preferably at disease progression) No
See also
  Status Clinical Trial Phase
Terminated NCT02080078 - A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Phase 1
Completed NCT00981721 - A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00351325 - A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies Phase 1
Completed NCT00295243 - Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies Phase 1
Recruiting NCT02347228 - Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00979134 - Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours Phase 1
Completed NCT00997945 - 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT05573724 - Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies Phase 1
Completed NCT03736473 - A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients Phase 1
Completed NCT01213160 - Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient Phase 1
Terminated NCT01219543 - A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. Phase 1
Completed NCT00572364 - Open Label, Dose Escalation Phase I Study of AZD2281 Phase 1
Completed NCT03363893 - Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Phase 1/Phase 2
Active, not recruiting NCT04606381 - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies Phase 1
Recruiting NCT05315167 - A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00879905 - A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT00473616 - Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan Phase 1
Recruiting NCT05159700 - A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01813474 - Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies Phase 1
Completed NCT01102400 - A Study of MEDI-575 in Patients With Advanced Solid Malignancies Phase 1